Agios Pharmaceuticals, Inc.

NASDAQ:AGIO

Biotechnology

Healthcare
$29.68 +1.50%

+$0.50 today

Market cap
$1.78B
Beta
0.59
P/E (TTM)
-4.7
EPS (TTM)
-$7.19
52W Low $22.24High $46.00

Volume 0.60M

Average 1.11M

AGIO Deferred Income Tax

The difference between tax expense recognized and tax actually paid in cash during the period.

Agios Pharmaceuticals, Inc.NASDAQ: AGIO

Deferred Income Tax · Q1 FY2026 · quarter ended Mar 2026

Deferred income tax outflow grows to $0

Q1 FY2026 deferred income tax was $0, compared with $0 a year earlier. Trailing-twelve-month deferred income tax was $0.

Context

  • Deferred income tax amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Deferred income tax increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly deferred income tax holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Deferred Income Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Deferred Income Tax history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Deferred Income Tax vs competitors

How AGIO compares with its peers on the latest reported figures

  • AGIO's LTM Mar 2026 deferred income tax of $0 is the 2nd largest of the 7 companies compared; the peer median is $0.
  • Deferred income tax amounts to 0.0% of revenue for AGIO, versus a peer median of 0.0%.
AGIO Competitors Peer median
Deferred Income Tax for AGIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PTCTPTC Therapeutics, Inc.LTM Jun 2026$13K -100.0%-95.6%0.0%
AGIOAgios Pharmaceuticals, Inc.LTM Mar 2026$0 ——0.0%
MIRMMirum Pharmaceuticals, Inc.LTM Jun 2026$0 ——0.0%
IRONDisc Medicine, Inc.LTM Sep 2026$0 ———
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$0 ——0.0%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$0 ——0.0%
PHARPharming Group N.V.LTM Mar 2026$0 ——0.0%
Peer median (excluding AGIO) $0-100.0%-95.6%0.0%

Competitors are the stored peer set for AGIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(356.51M)(231.8M)(352.09M)673.73M(412.78M)
Depreciation & Amortization9.24M8.56M6.62M5.65M5.18M
Deferred Income Tax00000
Stock-Based Compensation53.51M49.3M44.77M42.85M52.55M
Change in Working Capital(36.82M)(16.43M)(19.06M)(19.77M)(33.04M)
Accounts Receivables(4.38M)(2.21M)(604K)(1.3M)(6.47M)
Inventory0(8.49M)(10.58M)(8.54M)(5.3M)
Accounts Payables1.86M3.44M(8.73M)6.6M1.75M
Other Working Capital(34.31M)(9.17M)864K(16.53M)(23.02M)
Other Non-Cash Items(76.74M)(119.1M)23.69M(1.09B)15.12M
Operating Cash Flow(407.32M)(309.48M)(296.06M)(389.84M)(372.98M)
Capital Expenditures(5.74M)(4.88M)(999K)(1.69M)(4.32M)
Acquisitions (Net)0132.75M040K0
Purchases of Investments(1.38B)(1.03B)(417.93M)(1.54B)(641.76M)
Sales of Investments829.8M1.15B674.68M818.38M1.03B
Other Investing Activities1.8B0(16.18M)1.09B(10M)
Investing Cash Flow1.25B243.26M239.58M363.44M377.18M
Debt Repayment(578K)(331K)000
Common Stock Issued02.68M5.43M14.44M8.68M
Common Stock Repurchased(802.49M)0000
Dividends Paid00000
Other Financing Activities37.3M0000
Financing Cash Flow(765.77M)2.35M5.43M14.44M8.68M
Effect of Forex Changes00000
Net Change in Cash75.69M(63.87M)(51.05M)(11.96M)12.88M
Free Cash Flow(413.06M)(314.36M)(297.06M)(391.53M)(377.29M)

Agios Pharmaceuticals, Inc.

NASDAQ:AGIO

Intrinsic Alpha fair value

Locked

Current Price

$29.68

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.